EZH2 and prostate carcinoma: Moreover, combined treatment with the USP7-specific inhibitorP5091 and EZH2 inhibitors, such as GSK126, EPZ6438, and DZNep, inducedsynergistic inhibitory effects on cell migration, invasion, and sphere-formingpotential in prostate cancer cells.